The colorectal tumor microenvironment: The next decade

Cancer Microenvironment

Volumn 4, Issue 2, 2011, Pages 181-185

  Beauchemin, Nicole ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

CCL2; Chemokines; Colorectal cancer; Cytokines; DDR2; Inflammation; Microenvironment; miRNA

Indexed keywords

CYCLOOXYGENASE 2; INTERLEUKIN 1; INTERLEUKIN 6; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; RAS PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER RISK; CARNITINE PALMITOYL TRANSFERASE 1 GENE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; COLON CARCINOGENESIS; COLORECTAL TUMOR; COMPLEX FORMATION; CYTOKINE PRODUCTION; DISCOIDIN DOMAIN RECEPTOR 2 GENE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; GENETIC ASSOCIATION; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 81855176229     PISSN: 18752292     EISSN: 18752284     Source Type: Journal    
DOI: 10.1007/s12307-011-0074-7     Document Type: Article

References (34)

1. Smith SC, Theodorescu D (2009) Learning therapeutic lessons from metastasis suppressor proteins. Nat Rev Cancer 9(4):253-264
2. Nash GM, Gimbel M, Shia J, Nathanson DR, Ndubuisi MI, Zeng ZS, Kemeny N, Paty PB (2010) KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol 17(2):572-578
3. Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, Kondo C, Mizota A, Utsunomiya S, Muro K, Yatabe Y (2011) BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104(5):856-862
4. Park JH, Han SW, Oh DY, Im SA, Jeong SY, Park KJ, Kim TY, Bang YJ, Park JG (2011) Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Cancer Chemother Pharmacol (Feb. 22): [Epub ahead of print]
5. Ju HX, An B, Okamoto Y, Shinjo K, Kanemitsu Y, Komori K, Hirai T, Shimizu Y, Sano T, Sawaki A, Tajika M, Yamao K, Fujii M, Murakami H, Osada H, Ito H, Takeuchi I, Sekido Y, Kondo Y (2011) Distinct profiles of epigenetic evolution between colorectal cancers with and without metastasis. Am J Pathol 178(4):1835-1846
6. Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J, Prosper F, Garcia-Foncillas J (2009) Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 125(11):2737-2743
7. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Stampfer MJ, Rosner B, Speizer FE, Willett WC (1999) Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med 340(3):169-176 (Pubitemid 29063212)
8. Koushik A, Hunter DJ, Spiegelman D et al (2007) Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies. J Natl Cancer Inst 99(19):1471-1483
9. Yanovski SZ, Yanovski JA (2011) Obesity prevalence in the United States-up, down, or sideways? N Engl J Med 364(11):987-989
10. Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356:2131-2142 (Pubitemid 47010839)
11. Flossmann E, Rothwell PM (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369:1603-1613 (Pubitemid 46710123)
12. Sparmann A, Bar-Sagi D (2004) Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6:447-458 (Pubitemid 39469981)
13. Shchors K, Shchors E, Rostker F, Lawlor ER, Brown-Swigart L, Evan GI (2006) The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes Dev 20:1651-1656
14. Bierie B, Chung CH, Parker JS, Stover DG, Cheng N, Chytil A, Aakre M, Shyr Y, Moses HL (2009) Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest 119(6):1571-1582
15. Popivanova BK, Kostadinova FI, Furuichi K, Shamekh MM, Kondo T, Wada T, Egashira K, Mukaida N (2009) Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res 69(19):7884-7892
16. Loberg RD, Ying C, Craig M, Day LL, Sargent E, Neeley C, Wojno K, Snyder LA, Yan L, Pienta KJ (2007) Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res 67(19):9417-9424 (Pubitemid 47535932)
17. Qian B-Z, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature doi:10.1038/nature10138
18. Hsu CP, Chen YL, Huang CC, Chou CC, Liu CL, Hung CH, Kao TY, Chung YC (2011) Anti-interleukin-6 receptor antibody inhibits the progression in human colon carcinoma cells. Eur J Clin Invest 41(3):277-284
19. Febbraio MA, Rose-John S, Pedersen BK (2010) Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases? Clin Pharmacol Ther 87(4):396-398
20. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, Oshima M, Fujii C, Mukaida N (2008) Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest 118(2):560-570 (Pubitemid 351206546)
21. Sakai H, Yamada Y, Shimizu M, Saito K, Moriwaki H, Hara A (2010) Genetic ablation of Tnfalpha demonstrates no detectable suppressive effect on inflammation-related mouse colon tumorigenesis. Chem Biol Interact 184(3):423-430
22. Ghosh N, Chaki R, Mandal V, Mandal SC (2010) COX-2 as a target for cancer chemotherapy. Pharmacol Rep 62(2):233-244
23. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R (2007) High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 13:1472-1479 (Pubitemid 46450437)
24. Jedinak A, Dudhgaonkar S, Sliva D (2010) Activated macrophages induce metastatic behavior of colon cancer cells. Immunobiology 215:242-249
25. Mantovani A, Sica A, Allavena P, Garlanda C, Locati M (2009) Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunobiol 70(5):325-330
26. Arndt GM, Dossey L, Cullen LM, Lai A, Druker R, Eisbacher M, Zhang C, Tran N, Fan H, Retzlaff K, Bittner A, Raponi M (2009) Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 9:374
27. Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC (2001) Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol 167:3545-3549 (Pubitemid 32910793)
28. Gregory PA, Bracken CP, Bert AG, Goodall GJ (2008) Micro-RNAs as regulators of epithelialmesenchymal transition. Cell Cycle 7:3112-3118
29. Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, Hirata H, Giardina C, Dahiya R (2009) miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 28:1714-1724
30. Iliopoulos D, Drosatos K, Hiyama Y, Goldberg IJ, Zannis VI (2010) MicroRNA-370 controls the expression of MicroRNA-122 and Cpt1alpha and affects lipid metabolism. J Lipid Res 51(6):1513-1523
31. Rego RL, Foster NR, Smyrk TC, Le M, O'Connell MJ, Sargent DJ, Windschitl H, Sinicrope FA (2010) Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer 102:165-172
32. Olaso E, Badiola I, Crende O, Friedman SL et al (2011) Discoidin domain receptor 2 deficiency predisposes hepatic tissue to colon carcinoma metastasis. Gut in press
33. Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ (2002) Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94(7):513-521 (Pubitemid 34411290)
34. Fritzmann J, Morkel M, Besser D, Budczies J, Kosel F, Brembeck FH, Stein U, Fichtner I, Schlag PM, Birchmeier W (2009) Colorectal cancer expression profile that includes transforming growth factor beta inhibitor BAMBI predicts metastatic potential. Gastroenterology 137:165-175